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Potassium channels encoded by hERG (human ether-à-go-go-related gene) underlie the cardiac rapid
delayed rectiﬁer K+ current (IKr) and hERG mutations underpin clinically important repolarization disor-
ders. Virtually all electrophysiological investigations of hERG mutations have studied exclusively the
hERG1a isoform; however, recent evidence indicates that native IKr channels may be comprised of
hERG1a together with the hERG1b variant, which has a shorter N-terminus. Here, for the ﬁrst time, elec-
trophysiological effects were studied of a gain-of-function hERG mutation (N588K; responsible for the
‘SQT1’ variant of the short QT syndrome) on current (IhERG1a/1b) carried by co-expressed hERG1a/1b chan-
nels. There were no signiﬁcant effects of N588K on IhERG1a/1b activation or deactivation, but N588K IhERG1a/
1b showed little inactivation up to highly positive voltages (6+80 mV), a more marked effect than seen for
hERG1a expressed alone. IhERG1a/1b under action potential voltage-clamp, and the effects on this of the
N588K mutation, also showed differences from those previously reported for hERG1a. The ampliﬁed
attenuation of IhERG inactivation for the N588K mutation reported here indicates that the study of co-
expressed hERG1a/1b channels should be considered when investigating clinically relevant hERG channel
mutations, even if these reside outside of the N-terminus region.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
In recent years a novel cardiac repolarization disorder called the
short QT syndrome (SQTS) has been identiﬁed that is characterized
by marked abbreviation of the QT interval on the electrocardio-
gram, changes in T wave morphology, poor rate adaptation of the
QT interval and an increased risk of arrhythmia and sudden death
[1–4]. Gain-of-function mutations in three potassium (K+) channel
genes have been identiﬁed in SQTS patients: the SQT1 variant of
the syndrome is linked to mutations to KCNH2, whilst SQT2 and
SQT3 variants are associated, respectively, with mutations to
KCNQ1 and KCNJ2 [5–7]. With a strong correlation between the
SQTS and increased arrhythmia susceptibility [4,8], this syndrome
provides an important opportunity to understand the link between
accelerated cardiac repolarization and arrhythmogenesis; indeed,ncox).
al Research, Horsham, West
n and Sussex Medical School,
Y-NC-ND license.the SQTS has been proposed to provide a paradigm for understand-
ing the role of cardiac K+ channels in ventricular ﬁbrillation [9].
The ﬁrst cardiac K+ current implicated in the SQTS was the rapid
delayed rectiﬁer (IKr), the channel a subunit of which is encoded by
KCNH2 (alternative nomenclature hERG: human ether-à-go-go-re-
lated gene) [5,6]. IKr plays a critical role in ventricular action poten-
tial (AP) repolarization and, thereby, in determining the duration of
the QT interval [10]. SQT1 patients were found to possess an aspar-
agine to lysine substitution (N588K) in the S5-Pore linker region of
the hERG channel protein [5,6], resulting in attenuation of a rapid
C-type inactivation process that normally limits hERG current
(IhERG) amplitude at positive voltages [11,12]. In turn, this is envis-
aged to enable greater repolarizing current to ﬂow through SQT1
mutant than wild-type (WT) channels during cardiac APs [5,11–
13].
Although studies conducted to-date have provided insight into
the possible basis of abbreviated repolarization in SQT1 [5,11–
13], there is some question as to their physiological relevance. This
is because – in common with virtually all studies of recombinant
hERG channels that have been conducted to-date – all information
on the likely consequences for IKr kinetics of the N588K hERG
mutation comes from studies of the hERG1a isoform [5,11–14]. Re-
cent evidence, however, suggests that native cardiac IKr may not be
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expressed with an alternative transcript, hERG1b, an isoform with
a truncated N-terminus [15,16]. The ERG1b splice variant was ini-
tially identiﬁed in both mouse and human hearts and is identical to
the 1a isoform except for a truncated N-terminus [17,18]. It was
subsequently proposed not to be expressed at the protein level in
human heart [19]; however, the ERG1a and 1b isoforms have
now been found to co-exist in several species and are co-localized
in the T-tubules of ventricular myocytes [15]. They co-assemble to
form functional heteromeric channels with altered kinetics (partic-
ularly in respect of deactivation) that may more closely recapitu-
late native IKr compared to ERG1a alone [15,16]. Very recent
evidence of altered WT hERG channel gating for co-expressed hER-
G1a/1b [16,20] raises questions as to whether or not consequences
for native IKr of disease-causing hERG mutations, including those
that affect IhERG inactivation, can be considered to be adequately
recapitulated by studying hERG1a alone. Consequently, the present
study was conducted to determine the effects of the N588K hERG
SQT1 mutation on co-expressed hERG1a/1b channels. This report
shows for the ﬁrst time that, despite the fact that the location of
the S5-Pore linker in the hERG channel is distant from that of the
N-terminus, the effects of the SQT1 N588K hERG mutation on IhERG
carried by hERG1a/1b channels are more marked than those re-
ported previously for hERG1a alone.
Methods
Maintenance of hERG expressing cell lines. WT hERG1b in
pcDNA 3.1 was generously donated by Dr. Gail Robertson (Uni-
versity of Wisconsin). The construction of N588K hERG1a from
WT hERG in pcDNA 3.0 vector has been described previously
[12]. N588K hERG1b was made by replacement of the N-termi-
nus in N588K 1a with that of WT hERG1b. This was achieved
by 2-primer PCR of hERG1b (in pcDNA3.1) with the creation of
a SalI restriction site (located in the S2 domain of hERG). The
resulting PCR product was cut at SalI and HindIII sites and
sub-cloned into the hERG1a vector (in pcDNA3.0). Chinese Ham-
ster Ovary (CHO) cells were passaged using a non-enzymatic
agent (Splitase, AutogenBioclear) and plated out onto small ster-
ilised glass coverslips in 30 mm petri dishes containing Kaighn’s
modiﬁcation of Ham’s F12-K medium (Gibco), supplemented
with 10% foetal bovine serum (Gibco) and 200 lg ml1 gentami-
cin (Gibco). Prior to transfection, cells were plated out onto
small sterilised glass coverslips. After 24 h cells were co-trans-
fected with hERG and green ﬂuorescent protein (in pCMX; do-
nated by Dr. Jeremy Tavare) at a ratio of 2:1 using
Lipofectamine LTX (Invitrogen), according to the manufacturer’s
instructions. For the experiments performed using hERG1a and
1b co-expression, the cells were co-transfected with WT or
N588K hERG1a and 1b at a co-expression ratio of 1:1. Following
transfection, after 5–6 h incubation in serum-containing medium,
medium was replaced. Cells were incubated at 37 C for at least
1 day prior to electrophysiological study. Data from WT and
N588K hERG1a expressed alone (Fig. 3) derive from CHO cells
stably expressing WT or N588K hERG1a [12,21].
Electrophysiological recording. Data acquisition and recording
methods used were identical to those described in previous studies
of WT and N588K hERG1a from our laboratory [12,13,22]. Brieﬂy,
whole-cell voltage-clamp measurements were made at 37 C with
an external solution containing (in mM): 140 NaCl, 4 KCl, 2.5 CaCl2,
1 MgCl2, 10 Glucose and 5 HEPES (titrated to pH 7.45 with NaOH).
The pipette dialysis solution contained (in mM): 130 KCl, 1 MgCl2,
5 EGTA, 5 MgATP and 10 HEPES (titrated to pH 7.2 with KOH). Pip-
ette resistance ranged from 1.5–3.5 MX. Typically 80% series
resistance could be compensated. The action potential (AP) wave-forms used for ‘AP clamp’ experiments (Fig. 4) are identical to
those described in [13].
Data analysis and presentation. The numerical equation for volt-
age-dependence of activation is described in [12]. The use of a con-
ventional ‘availability’ voltage-protocol to quantify the voltage-
dependence of IhERG inactivation (e.g. [11,12]) is contingent upon
the ability to inactivate fully IhERG with strong membrane depolar-
ization. However, in this study N588K IhERG1a/1b could not be sub-
stantially inactivated by depolarizations as positive as +80 mV
(Fig. 3) and so we adopted an approach to quantify inactivation
similar to that used in a recent investigation of inactivation-atten-
uating hERG mutations [22]. For each of several test voltages (+20,
+40, +60, +80 mV; Fig. 3) a 2 s depolarization (to activate/inactivate
IhERG) was followed by a brief (2 ms) hyperpolarization to 100 mV
(to relieve inactivation) and then inactivation was re-established
by a 2 s depolarization to the same potential as the ﬁrst step. The
magnitude of the current transient during the third step of the pro-
tocol indicated IhERG at each voltage after pronounced recovery
from inactivation, whilst the sustained current at the end of the
ﬁrst pulse was taken as representing current remaining after inac-
tivation was complete at the relevant test voltage. The ratio of the
two was used to assess the fraction of inactivated IhERG at each test
voltage.
Data were analysed using Clampﬁt 8 (Axon Instruments), Excel
2002 and Prism v3 (Graphpad Inc.) software. Throughout, data are
presented as the mean ± standard error of the mean (SEM). Statis-
tical analysis was carried out using a Student’s t-test and one or
two-way analysis of variance (ANOVA) as appropriate, with Bon-
ferroni post-test using Prism v3 (Graphpad Inc.). P values of less
than 0.05 were taken to be statistically signiﬁcant.
Results and discussion
Fig. 1A shows representative records of IhERG elicited by a depo-
larizing voltage command to +20 mV from a holding potential of
80 mV (protocol shown as inset; [12,13,23]), for each of singly-
expressed WT (Ai) and N588K (Aii) hERG1b channels. For both
channels, IhERG1b amplitude during the depolarizing voltage com-
mand was much greater than the subsequent IhERG1b ‘tail’ visible
on repolarization to 40 mV; tail current deactivation was also ex-
tremely rapid (with mono-exponential time-constants <30 ms for
both WT and N588K hERG1b). The lack of a resurgent IhERG tail
and extremely rapid deactivation time-course for WT IhERG1b indi-
cates that, concordant with previous evidence [17,18], WT IhERG1b
expressed alone does not recapitulate native IKr; therefore all fur-
ther experiments were conducted using co-expressed hERG1a/1b.
Fig. 1B shows IhERG families for each of WT (Bi) and N588K (Bii) IhER-
G1a/1b elicited by commands to a range of test voltages (Fig. 1B low-
er traces; cf. [12]). WT IhERG1a/1b increased progressively with
depolarization up to 10 mV and then declined at more positive
potentials, whereas N588K IhERG1a/1b increased progressively up to
+40/+50 mV, declining only slightly at +60 mV. Fig. 1Ci illustrates
this graphically for mean end-pulse current data. Resurgent IhERG1a/
1b tails for WT hERG were evident, whilst for N588K IhERG1a/1b tails
were markedly smaller than pulse currents following commands to
positive voltages (Fig. 1Bii). Normalized peak IhERG1a/1b tail – volt-
age relations were plotted (Fig. 1Cii) to ascertain parameters
describing voltage-dependent activation for the two channels (cf.
[12]). The calculated half-maximal activation voltage (V0.5) values
for WT and N588K IhERG1a/1b were, respectively, 27.0 ± 0.4 mV
and 27.3 ± 1.1 mV, with corresponding k values of 7.4 ± 0.4 and
8.0 ± 1.0 mV (n = 8 cells each; P > 0.05 for both). These values are
signiﬁcantly more negative (P < 0.001) than those we have previ-
ously reported for WT and N588K IhERG1a alone, under identical
recording conditions (20.1 ± 0.1 and22.4 ± 0.6 mV, respectively,
Fig. 1. I–V relations for WT and N588K IhERG1a/1b. (A) Traces of WT (Ai) and N588K (Aii) IhERG1b elicited by protocol shown in panel inset. (B) Traces of WT (Bi) and N588K (Bii)
IhERG1a/1b elicited by 2 s depolarizations ranging from 40 to + 60 mV, from a holding potential of 80 mV. The repolarization step to 40 mV produced the resultant outward
Itail. (C) Ci End-pulse currents normalised to the current observed at 0 mV and then plotted against membrane potential. Cii Plots of the peak Itails on repolarization to 40 mV
against membrane potential for WT and N588K hERG1a/1b. For Cii data for each cell were normalised to the maximal Itail recorded; mean data were ﬁtted with a Boltzmann
equation to give V0.5 values of 27.0 ± 0.4 and 27.3 ± 1.1 mV for WT 1a/1b and N588K 1a/1b-hERG, respectively, with respective k values of 7.4 ± 0.4 and 8.0 ± 1.0 mV (n = 8
for each).
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37 C, the N588K mutation alters rectiﬁcation of IhERG1a/1b, but
without signiﬁcantly altering the voltage-dependence of activation
(cf. [12]).
In order to compare IhERG deactivation between WT and N588K
IhERG1a/1b the protocol shown above Fig. 2A (inset) was used [12]
and the decline of IhERG1a/1b tails at different repolarization voltages
was compared using bi-exponential tail current ﬁtting. There was
no signiﬁcant difference between WT and mutant IhERG1a/1b in
either fast (Fig. 2Bi) or slow (Fig. 2Bii) time-constants of deactiva-tion, nor in the relative contributions of the fast/slow deactivating
components (Fig. 2Biii; n = 7 cells each). The deactivation time-
course for WT and N588K IhERG1a/1b was, however, faster than that
of the corresponding hERG1a channels (data not shown),
consistent with accelerated deactivation reported previously for
WT hERG1a/1b [16,18,20]. A plot of the fully-activated current–
voltage (I–V) relation derived from this protocol (Fig. 2C; cf.
[12,24]) conﬁrmed impaired rectiﬁcation of N588K IhERG1a/1b com-
pared to WT IhERG1a/1b, accompanied by a modest positive-shift in
reversal potential (from 85.2 ± 0.4 mV to 78.7 ± 1.9 mV; n = 7
Fig. 2. Deactivation and the fully activated I–V relation. (A) Representative traces of WT (Ai) and N588K (Aii) IhERG1a/1b elicited by the protocol shown in the inset. (B) Plots of
the fast (Bi) and slow (Bii) time-constants of deactivation for WT and N588K hERG1a/1b against membrane potential (n = 7, for each). Biii shows proportion of deactivation
that can be attributed to the fast component for WT and N588K hERG1a/1b (n = 7). (C) The peak Itail for WT and N588K hERG1a/1b plotted against the respective membrane
potential and normalised to the peak outward Itail observed for each individual cell (n = 7).
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(N588K)). These effects of the N588K hERG mutation are similar to
those reported previously for hERG1a alone [12].
Recent evidence suggests inactivation gating of WT IhERG1a/1b is
altered compared to that of WT IhERG1a [16]. Given this, and also
that the major reported effect of the N588K mutation on IhERG1a
is on the voltage-dependence of inactivation [11,12], it was imper-ative to determine effects of the N588K mutation on IhERG1a/1b. The
three-step protocol shown as an inset of Fig. 3A and B (see ‘Methods’
and [22]) was used to assess fractional inactivation of IhERG1a/1b.
As shown in Fig. 3A, at each of the 4 positive membrane potentials
examined, WT IhERG1a/1b was substantially inactivated. By contrast,
however, N588K IhERG1a/1b exhibited only a small transient
component at any voltage, with a large sustained component
Fig. 3. IhERG fractional inactivation. Representative current traces for WT (A) and N588K hERG1a/1b (B) that were elicited using the protocol shown in the inset (protocol not
drawn to scale). The traces focus on the current proﬁle during the second and third steps of the protocol, the area is indicated by the dashed box area in the protocol. The
horizontal dashed line represents zero current. (C) The fraction of inactivated IhERG at different membrane potentials shown for WT 1a (n = 5 cells), WT 1a/1b (n = 5 cells),
N588K 1a (n = 5 cells) and N588K hERG1a/1b (n = 6 cells). n.s denotes no statistical signiﬁcance, # denotes statistical signiﬁcance of P < 0.01 and § denotes statistical
signiﬁcance of P < 0.001. Mean ± SEM values for WT 1a and N588K 1a at +20 mV highlighted by dashed bars are identical to those in [22].
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any of the voltages examined. Fig. 3C shows mean data for WT and
N588K IhERG1a/1b, with mean data for WT and N588K IhERG1a also in-
cluded for comparison. There was little difference between WT
IhERG1a and IhERG1a/1b in fractional current inactivation at any volt-
age, whilst by contrast there was a very substantial difference at
each voltage between N588K IhERG1a and IhERG1a/1b. Therefore, our
data show that the inactivation-attenuating effects of the N588K
mutation were markedly greater when co-expressed hERG1a and
1b were studied than when hERG1a alone was studied.
In order to assess the physiological consequences of the N588K
mutation for co-expressed hERG1a and 1b, AP clamp experiments
were performed. Fig. 4A shows representative currents for WT
(Fig. 4Ai) and N588K (Fig. 4Aii) IhERG1a/1b, elicited by a human ven-
tricular AP command [13]. For WT IhERG1a/1b there was little current
immediately following the AP upstroke, with current developing
progressively throughout the AP plateau, declining during the ter-
minal repolarization phase. Mean data from 14 cells showed that
maximal WT IhERG1a/1b during AP repolarization occurred at
22.3 ± 1.0 mV. This value is signiﬁcantly more positive than that
we have recently reported for WT IhERG1a during an identical AP
command (37.6 ± 1.7 mV; [13]) and the earlier peak IhERG1a/1b is
consistent with faster deactivation together with accelerated acti-
vation and recovery from inactivation of IhERG1a/1b recently re-
ported [16]. For N588K IhERG1a/1b, current increased rapidly
following the AP upstroke and peaked early during the AP plateau.
Current then declined, with a relatively rapid decline during the ﬁ-
nal AP repolarization phase. Peak N588K IhERG1a/1b occurred at
+27.1 ± 0.2 mV (n = 14), which compares with a value of
+24.6 ± 0.6 mV for IhERG1a during the same waveform [13]
(P < 0.001). Current density plots for peak repolarizing IhERG1a/1b
(Fig. 4C) show a markedly greater maximal repolarizing current
for N588K than for WT IhERG1a/1b during a ventricular AP command
waveform (P < 0.001).
For hERG1a, a differential effect of the N588K mutation on cur-
rent during ventricular and Purkinje ﬁbre APs has been suggested
to contribute toward U wave formation and a pro-arrhythmic sub-
strate in SQT1 [11,12]. Therefore, AP clamp experiments with aPurkinje ﬁbre (PF) AP command [12] were also performed
(Fig. 4B). For bothWT (Bi) and N588K (Bii) IhERG1a/1b, current during
the PF AP was bow-shaped, peaking at 17.4 ± 3.0 mV (n = 13) and
9.0 ± 0.3 mV (n = 14; P < 0.001), respectively, (this compares with
45.6 ± 1.6 and 14.8 ± 0.3 mV for WT and N588K IhERG1a during
the same PF waveform under identical conditions [12]). Fig. 4C
shows that peak repolarization current densities for both WT and
N588K conditions during the PF AP were signiﬁcantly lower than
those during the ventricular AP command, and that the N588K
mutation produced only a small increase in maximal repolarizing
IhERG1a/1b amplitude, that was not statistically signiﬁcant
(P > 0.05). Thus, effects of the N588K mutation on current during
the PF AP were small for co-expressed hERG1a/1b (smaller than
for hERG1a alone under identical conditions [12]), consistent with
enhanced heterogeneity in repolarizing IKr between ventricular
and PF APs in SQT1.
To-date there is comparatively little information available on
the effects of clinically relevant hERG mutations on hERG1a/1b
heteromers [16]. This is the ﬁrst study to have investigated hER-
G1a/1b heteromeric channels in the context of the short QT syn-
drome and it is only the second that provides detailed
information on biophysical properties of WT IhERG1a/1b, at a physio-
logically relevant temperature. Our ﬁndings support the notion
that the contribution to ventricular repolarization of current
through heteromeric WT hERG1a/1b channels differs from that of
hERG1a alone [16]. More remarkably, they demonstrate for the
ﬁrst time a marked difference in the inactivation-attenuating effect
of a pathologically relevant hERGmutation when heteromeric hER-
G1a/1b channels are studied. N-terminal deletion has been demon-
strated to slow hERG1a inactivation [25] and the ampliﬁed effect of
the N588K mutation on fractional inactivation of IhERG1a/1b seen
here may reﬂect synergy between the mutation’s disruption of
the role of the S5-Pore linker in the inactivation process and the
potential for reduced stabilization of inactivation due to the fact
that 1a/1b heteromers have fewer N-terminal contacts to interact
with the internal S4–S5 linker [16,25]. Whilst it may be intuitively
obvious that the study of hERG1b-speciﬁc mutations [16] or
N-terminal long QT syndrome (LQTS) mutations (20% of
Fig. 4. IhERG1a/1b proﬁle during ventricular and Purkinje ﬁbre AP waveforms. (A) Representative traces of WT (Ai) and N588K (Aii) IhERG1a/1b elicited by ventricular AP
command waveform (shown overlain; n = 14 for both). (B) Representative traces of WT (Bi; n = 13) and N588K (Bii; n = 14) IhERG1a/1b elicited by a Purkinje ﬁbre AP command
waveform. (C) Plots of maximal current density for WT and N588K hERG1a/1b during ventricular and Purkinje ﬁbre AP command waveforms. § denotes statistical signiﬁcance
of P < 0.001.
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warrants the study of hERG1a/1b heteromeric channels, until
now there may not have been a clear rationale to adopt this
approach when studying mutations that are distant from the
N-terminus. The present study provides a clear demonstration that
such mutations cannot be assumed to have identical effects on
hERG1a/1b to those found for hERG1a alone. Consequently, it
may be prudent to incorporate more widely the study of
hERG1a/1b heteromeric channels when investigating biophysical
consequences of hERG mutations in both the LQTS and SQTS.
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